Please see full Prescribing Information for ANJESO, including Important Safety Information and Boxed Warning, at www.anjeso.com.
Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings.
We currently have multiple therapeutic candidates across early, mid and late-stage clinical development, including a FDA approved non-opioid therapy for use in the acute care setting.
Our product pipeline contains valuable therapeutic product candidate options for patients and healthcare providers in acute care settings.
ANJESO (meloxicam) injection Product Pipeline
Baudax Bio Announces Full Commercial Launch of ANJESO™ and Receipt of Unique C-Code and Pass-Through Payment Status Effective July 1, 2020
Baudax Bio Secures $50 Million Credit Facility
Baudax Bio Reports First Quarter 2020 Financial Results
Baudax Bio Announces Presentation of New Phase IIIb ANJESO™ Data at Digestive Disease Week 2020
Baudax Bio Announces Change in Location of its 2020 Annual Meeting of Shareholders to its Corporate Headquarters
Baudax Bio Announces Presentation of New Phase IIIb ANJESO™ Data at the 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting
Baudax Bio Announces U.S. Availability of ANJESO™ (meloxicam) Injection for the Management of Moderate to Severe Pain
Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Baudax Bio Announces Closing of $25 Million Public Offering of Securities
Stay informed and receive company updates straight to your inbox.